Nanoliposome adjuvant induced a robust mucosal and systemic response towards an amebiasis antigen. Vaccine induced mucosal IgA inhibited adherence of E. histolytica to target cells in vitro. This adjuvant is compatible with the use of all-trans retinoic acid as a co-adjuvant. The adjuvant showed potential to elicit protective response against E. histolytica.